# Data Extraction Form - Type 2 Diabetes Drug Sequencing NMA

## Instructions for Data Extractors

### General Guidelines
- **Double Extraction**: All data extracted independently by two reviewers
- **Source Documentation**: Record page/table/figure numbers for each data point
- **Uncertainty Resolution**: Flag uncertainties for discussion
- **Quality Indicators**: Assess confidence in each extracted data point
- **Standardization**: Use consistent terminology and units

### Data Entry Rules
- Use "NR" for Not Reported
- Use "NA" for Not Applicable
- Record exact values as reported (do not convert units)
- Include confidence intervals when available
- Document any calculations performed

## Section 1: Study Characteristics

### Basic Information
- **PMID**: ____________________
- **NCT_ID**: ____________________ (if available)
- **Title**: ____________________
- **Authors**: ____________________
- **Journal**: ____________________
- **Publication Year**: ____________________
- **DOI**: ____________________

### Study Design
- **Design Type**: ____________________ (RCT, Observational, Meta-analysis)
- **Phase**: ____________________ (if applicable)
- **Countries**: ____________________
- **Number of Centers**: ____________________
- **Funding Source**: ____________________
- **Registration**: ____________________

### Sample Size and Follow-up
- **Randomized**: ____________________
- **Completed**: ____________________
- **Analyzed**: ____________________
- **Follow-up Duration (months)**: ____________________
- **Completion Rate (%): ____________________

## Section 2: Population Characteristics

### Eligibility Criteria
- **Inclusion**: ____________________
- **Exclusion**: ____________________

### Baseline Characteristics
**Age (years):**
- Mean: ____________________ SD: ____________________
- Range: ____________________

**Sex (% male): ____________________**

**Race/Ethnicity Distribution:**
- White: ____________________%
- Asian: ____________________%
- Black: ____________________%
- Hispanic: ____________________%
- Other: ____________________%

**Diabetes Duration (years):**
- Mean: ____________________ SD: ____________________

**Baseline HbA1c (%):**
- Mean: ____________________ SD: ____________________

**Baseline BMI (kg/m²):**
- Mean: ____________________ SD: ____________________

**Baseline eGFR (mL/min/1.73m²):**
- Mean: ____________________ SD: ____________________

**Comorbidities (%):**
- ASCVD: ____________________
- CKD: ____________________
- Heart Failure: ____________________
- Hypertension: ____________________

## Section 3: Intervention Details

### Treatment Arms
**Arm 1:**
- Drug Class: ____________________
- Specific Drug: ____________________
- Dose: ____________________
- Frequency: ____________________
- Background Therapy: ____________________
- Participants: ____________________

**Arm 2:**
- Drug Class: ____________________
- Specific Drug: ____________________
- Dose: ____________________
- Frequency: ____________________
- Background Therapy: ____________________
- Participants: ____________________

**Arm 3 (if applicable):**
- Drug Class: ____________________
- Specific Drug: ____________________
- Dose: ____________________
- Frequency: ____________________
- Background Therapy: ____________________
- Participants: ____________________

## Section 4: Outcome Measures

### Primary Outcomes

#### 1. Composite Cardiovascular Outcomes
- **Definition**: ____________________ (MACE-3, MACE-4, etc.)
- **Time Point (months)**: ____________________

**Arm 1:**
- Events: ____________________ / ____________________ participants
- Effect Size: ____________________ (HR/OR/RR with 95% CI)

**Arm 2:**
- Events: ____________________ / ____________________ participants
- Effect Size: ____________________ (HR/OR/RR with 95% CI)

**Arm 3:**
- Events: ____________________ / ____________________ participants
- Effect Size: ____________________ (HR/OR/RR with 95% CI)

#### 2. eGFR Decline ≥40%
- **Definition**: ____________________
- **Time Point (months)**: ____________________

**Arm 1:**
- Events: ____________________ / ____________________ participants
- Effect Size: ____________________ (HR/OR/RR with 95% CI)

**Arm 2:**
- Events: ____________________ / ____________________ participants
- Effect Size: ____________________ (HR/OR/RR with 95% CI)

**Arm 3:**
- Events: ____________________ / ____________________ participants
- Effect Size: ____________________ (HR/OR/RR with 95% CI)

#### 3. End-Stage Kidney Disease (ESKD)
- **Definition**: ____________________
- **Time Point (months)**: ____________________

**Arm 1:**
- Events: ____________________ / ____________________ participants
- Effect Size: ____________________ (HR/OR/RR with 95% CI)

**Arm 2:**
- Events: ____________________ / ____________________ participants
- Effect Size: ____________________ (HR/OR/RR with 95% CI)

**Arm 3:**
- Events: ____________________ / ____________________ participants
- Effect Size: ____________________ (HR/OR/RR with 95% CI)

#### 4. Severe Hypoglycemia
- **Definition**: ____________________
- **Time Point (months)**: ____________________

**Arm 1:**
- Events: ____________________ / ____________________ participants
- Effect Size: ____________________ (HR/OR/RR with 95% CI)

**Arm 2:**
- Events: ____________________ / ____________________ participants
- Effect Size: ____________________ (HR/OR/RR with 95% CI)

**Arm 3:**
- Events: ____________________ / ____________________ participants
- Effect Size: ____________________ (HR/OR/RR with 95% CI)

### Secondary Outcomes

#### 5. HbA1c Change (%)
- **Time Point (weeks)**: ____________________

**Arm 1:**
- Baseline: ____________________ SD: ____________________
- Endpoint: ____________________ SD: ____________________
- Change: ____________________ SD: ____________________
- Mean Difference: ____________________ (95% CI)

**Arm 2:**
- Baseline: ____________________ SD: ____________________
- Endpoint: ____________________ SD: ____________________
- Change: ____________________ SD: ____________________
- Mean Difference: ____________________ (95% CI)

**Arm 3:**
- Baseline: ____________________ SD: ____________________
- Endpoint: ____________________ SD: ____________________
- Change: ____________________ SD: ____________________
- Mean Difference: ____________________ (95% CI)

#### 6. Weight Change (kg)
- **Time Point (weeks)**: ____________________

**Arm 1:**
- Baseline: ____________________ SD: ____________________
- Endpoint: ____________________ SD: ____________________
- Change: ____________________ SD: ____________________
- Mean Difference: ____________________ (95% CI)

**Arm 2:**
- Baseline: ____________________ SD: ____________________
- Endpoint: ____________________ SD: ____________________
- Change: ____________________ SD: ____________________
- Mean Difference: ____________________ (95% CI)

**Arm 3:**
- Baseline: ____________________ SD: ____________________
- Endpoint: ____________________ SD: ____________________
- Change: ____________________ SD: ____________________
- Mean Difference: ____________________ (95% CI)

#### 7. Individual CV Events
**Myocardial Infarction:**
- Arm 1 Events: ____________________
- Arm 2 Events: ____________________
- Arm 3 Events: ____________________

**Stroke:**
- Arm 1 Events: ____________________
- Arm 2 Events: ____________________
- Arm 3 Events: ____________________

**CV Death:**
- Arm 1 Events: ____________________
- Arm 2 Events: ____________________
- Arm 3 Events: ____________________

**Heart Failure Hospitalization:**
- Arm 1 Events: ____________________
- Arm 2 Events: ____________________
- Arm 3 Events: ____________________

**All-Cause Mortality:**
- Arm 1 Events: ____________________
- Arm 2 Events: ____________________
- Arm 3 Events: ____________________

## Section 5: Moderator Variables

### Baseline Subgroup Data (if available)

#### By ASCVD Status
- **With ASCVD:**
  - Arm 1: n=____________________, Effect: ____________________
  - Arm 2: n=____________________, Effect: ____________________
  - Arm 3: n=____________________, Effect: ____________________

- **Without ASCVD:**
  - Arm 1: n=____________________, Effect: ____________________
  - Arm 2: n=____________________, Effect: ____________________
  - Arm 3: n=____________________, Effect: ____________________

#### By CKD Status
- **CKD Present:**
  - Arm 1: n=____________________, Effect: ____________________
  - Arm 2: n=____________________, Effect: ____________________
  - Arm 3: n=____________________, Effect: ____________________

- **No CKD:**
  - Arm 1: n=____________________, Effect: ____________________
  - Arm 2: n=____________________, Effect: ____________________
  - Arm 3: n=____________________, Effect: ____________________

#### By BMI Category
- **BMI <30:**
  - Arm 1: n=____________________, Effect: ____________________
  - Arm 2: n=____________________, Effect: ____________________
  - Arm 3: n=____________________, Effect: ____________________

- **BMI ≥30:**
  - Arm 1: n=____________________, Effect: ____________________
  - Arm 2: n=____________________, Effect: ____________________
  - Arm 3: n=____________________, Effect: ____________________

## Section 6: Study Quality and Risk of Bias

### Randomization and Allocation
- Random Sequence Generation: ____________________ (Low/High/Unclear)
- Allocation Concealment: ____________________ (Low/High/Unclear)

### Blinding
- Participants: ____________________ (Low/High/Unclear)
- Personnel: ____________________ (Low/High/Unclear)
- Outcome Assessors: ____________________ (Low/High/Unclear)

### Outcome Data
- Incomplete Data: ____________________ (Low/High/Unclear)
- Selective Reporting: ____________________ (Low/High/Unclear)
- Other Bias: ____________________ (Low/High/Unclear)

### Overall Risk of Bias: ____________________ (Low/High/Unclear)

## Section 7: Data Extraction Quality

### Extractor Information
- **Primary Extractor**: ____________________ Date: __________
- **Secondary Extractor**: ____________________ Date: __________

### Confidence Assessment
- **Overall Confidence**: ____________________ (High/Medium/Low)
- **Key Uncertainties**: ____________________
- **Discrepancies**: ____________________
- **Resolution**: ____________________

### Notes and Comments
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________

## Data Entry Validation Checklist

### Before Submission
- [ ] All fields completed or marked NR/NA
- [ ] Page numbers documented for each data point
- [ ] Effect sizes with confidence intervals
- [ ] Sample sizes match across outcomes
- [ ] Units are consistent and documented
- [ ] Both extractors agree on key outcomes
- [ ] Uncertainties clearly flagged

### After Entry
- [ ] Data entered into database
- [ ] Validation checks completed
- [ ] Discrepancies resolved
- [ ] Quality assessment documented

*Data Extraction Form Version 1.0 - October 12, 2025*
